Vicore has carried out a primary issuance of 10,000,000 shares at a subscription price of SEK 20 per share, raising gross proceeds of SEK 200 million.
Vicore is a clinical-stage pharmaceutical company focused on developing innovative medicines in severe diseases where the Angiotensin II type 2 receptor (AT2R) plays an important role. The Company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary artery hypertension (PAH). VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2 receptor agonists. VP04 develops a clinically validated digital therapeutic for pulmonary fibrosis patients.
Carnegie, Pareto Securities, Van Lanschot Kempen and Zonda Partners acted as Joint Bookrunners. Baker McKenzie acted as legal advisor to the Joint Bookrunners with a capital markets team consisting of Henric Roth and Sophie Gidlund from the Stockholm office and Megan Schellinger from the London office.